Antiproliferative effect of two novel COX-2 inhibitors on human keratinocytes

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 2, 2013, Pages 133-141

  Sticozzi, Claudia ^a   Belmonte, Giuseppe ^b   Cervellati, Franco ^a   Di Capua, Angela ^b   Maioli, Emanuela ^b   Cappelli, Andrea ^b   Giordani, Antonio ^c   Biava, Mariangela ^d   Anzini, Maurizio ^b   Valacchi, Giuseppe ^a,e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Rotta Research Laboratorium   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Kyung Hee University   (South Korea)

Author keywords

1,5 Diarylpyrrole 3 alkopyrrole 3 alkoxyethyl ethers; COX 2 inhibitor; Cyclin D1; p21

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ESTER; ETHER DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; ROFECOXIB; UNCLASSIFIED DRUG; VA 428; VA 441;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KERATINOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION; HUMANS; KERATINOCYTES; NF-KAPPA B; PYRROLES; RNA, MESSENGER; SULFONES;

EID: 84875404769     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.02.009     Document Type: Article

References (43)

1. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas, and L.J. Thal Alzheimer's disease cooperative study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826
2. K.M. Ansari, J.E. Rundhaug, and S. Fischer Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation Mol. Cancer Res. 6 2008 1003 1016
3. M. Anzini, M. Rovini, A. Cappelli, S. Vomero, F. Manetti, M. Botta, L. Sautebin, A. Rossi, C. Pergola, C. Ghelardini, M. Norcini, A. Giordani, F. Makovec, P. Anzellotti, P. Patrignani, and M. Biava Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity J. Med. Chem. 51 15 2008 4476 4481
4. A. Aoki-Yoshida, R. Aoki, and Y. Takayama Protective effect of pyruvate against UVB-induced damage in HaCaT human keratinocytes J. Biosci. Bioeng. 2012 doi:pii:S1389-1723(12)00455-0
5. M. Biava, G.C. Porretta, G. Poce, C. Battilocchio, M. Botta, F. Manetti, M. Rovini, A. Cappelli, L. Sautebin, A. Rossi, C. Pergola, C. Ghelardini, N. Galeotti, F. Makovec, A. Giordani, P. Anzellotti, S. Tacconelli, P. Patrignani, and M. Anzini Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents Curr. Med. Chem. 18 10 2011 1540 1554
6. R.S. Bresalier, V.E. Friedewald Jr.; R.E. Rakel, W.C. Roberts, and G.W. Williams The editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk Am. J. Cardiol. 96 11 2005 1589 1604
7. S. Briganti, and M. Picardo Antioxidant activity, lipid peroxidation and skin diseases What's new Dermatol. Venereol. 17 6 2003 663 669
8. K.S. Chun, H.C. Lao, and R. Langenbach The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways J. Biol. Chem. 285 51 2010 39672 39681
9. D. Creamer, M. Allen, R. Jaggar, R. Stevens, R. Bicknell, and J. Barker Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor Arch. Dermatol. 138 6 2002 791 796
10. W. Cui, C.H. Yu, and K.Q. Hu In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells Clin. Cancer Res. 11 22 2005 8213 8221
11. D.L. DeWitt Cox-2-Selective Inhibitors: the new super aspirins Mol. Pharm. 55 1999 625631
12. A. Fioravanti, L. Tinti, N.A. Pascarelli, A. Di Capua, A. Lamboglia, A. Cappelli, M. Biava, A. Giordani, S. Niccolini, M. Galeazzi, and M. Anzini In vitro effects of VA441, a new selective cyclooxygenase-2 inhibitor, on human osteoarthritic chondrocytes exposed to IL-1β J. Pharmacol. Sci. 120 1 2012 6 14
13. S.M. Fischer Prostaglandins and cancer Front Biosci. 2 1997 d482 d500
14. S.M. Fischer, H.H. Lo, G.B. Gordon, K. Seibert, G. Kelloff, R.A. Lubet, and C.J. Conti Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light induced skin carcinogenesis Mol. Carcinog. 25 1999 231 240
15. S. Fries, T. Grosser, T.S. Price, J.A. Lawson, S. Kapoor, S. De Marco, M.T. Pletcher, T. Wiltshire, and G.A. FitzGerald Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2 Gastroenterology 130 2006 55 64
16. T. Grosser, S. Fries, and G.A. FitzGerald Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 116 1 2006 4 15
17. kip1 and cell cycle arrest Cancer Res. 64 2004 1369 1376
18. S. Hernandez-Diaz, and L.A. Garcia Rodriguez Nonsteroidal anti-inflammatory drugs and risk of lung cancer Int. J. Cancer. 120 2007 1565 1572
19. Y. Higashi, T. Kanekura, and T. Kanzaki Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression Int. J. Cancer. 86 5 2000 667 671
20. P.P. Hu, X. Shen, D. Huang, Y. Liu, C. Counter, and X.F. Wang The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta J. Biol. Chem. 274 50 1999 35381 35387
21. G. Kauffman Aspirin-induced gastric mucosal injury: lessons learned from animal models Gastroenterology 96 2 Pt 2 Suppl. 1989 606 614
22. T. Kawamori, C.V. Rao, K. Seibert, and B.S. Reddy Chemopreventive activity of celeCOXib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis Cancer Res. 58 1998 409 412
23. M. Khan, and A. Fraser Cox-2 inhibitors and the risk of cardiovascular thrombotic events Ir. Med. J. 105 4 2012 119 121
24. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 4 2001 402 408
25. T.J. Maier, K. Schilling, R. Schmidt, G. Geisslinger, and S. Grosch Cyclooxygenase-2 (COX-2) dependent and independent anticarcinogenic effect of celecoxib in human colon carcinoma cells Biochem. Pharmacol. 69 2004 1469 1478
26. E. Maioli, C. Torricelli, and V. Fortino Functional interactions of protein kinase A and C in signalling networks: a recapitulation Cell. Mol. Life Sci. 63 6 2006 637 641
27. R.P. Mason, M.F. Walter, H.P. McNulty, S.F. Lockwood, J. Byun, C.A. Day, and R.F. Jacob Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: A mechanism of cardiotoxicity S. J. Cardiovasc. Pharmacol. 47 1 2006 S7 S14
28. A.P. Paiotti, P. Marchi, S.J. Miszputen, C.T. Oshima, M. Franco, and D.A. Ribeiro The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis In Vivo. 26 3 2012 381 393
29. P. Patrignani, M.R. Panara, A. Greco, O. Fusco, C. Natoli, S. Iacobelli, F. Cipollone, A. Ganci, C. Créminon, and J. Maclouf Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J. Pharmacol. Exp. Ther. 271 1705 1994 1712
30. T.D. Penning, J.J. Tally, S.R. Bertenshaw, J.S. Carter, P.W. Collins, S. Docter, M.J. Graneto, L.F. Lee, J.W. Malecha, J.M. Miyashiro, R.S. Rogers, D.J. Rogier, S.S. Yu, G.D. Anderson, E.G. Burton, J.N. Cogburn, S.A. Gregory, C.M. Koboldt, W.E. Perkins, K. Seibert, A.W. Veenhuizen, Y.Y. Zhang, and P.C. Isakson Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celeCOXib) J. Med. Chem. 40 1997 1347 1365
31. P. Prasit, Z. Wang, C. Brideau, C.C. Chan, S. Charleson, W. Cromlish, D. Ethier, J.F. Evans, A.W. Ford-Hutchinson, J.Y. Gauthier, R. Gordon, J. Guay, M. Gresser, S. Kargman, B. Kennedy, Y. Leblanc, S. Léger, J. Mancini, G.P. O'Neill, M. Ouellet, M.D. Percival, H. Perrier, D. Riendeau, I. Rodger, and R. Zamboni The discovery of rofeCOXib, [MK 966, Vioxx, 4-(4′- methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor Bioorg. Med. Chem. Lett. 9 1999 1773 1778
32. L.A. Rodriguez, and P. Patrignani The ever growing story of cyclo-oxygenase inhibition Lancet 368 2006 1745 1747
33. A.J. Scheen Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of cox-2-selective non-steroidal anti-inflammatory drugs? Rev. Med. Liege 59 565-569 2004 2004
34. A.H. Schönthal Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy Br. J. Cancer 97 11 2007 1465 1468
35. S.Y. Shin, C.G. Kim, Y. Lim, and Y.H. Lee The ETS family transcription factor ELK-1 regulates induction of the cell cycle-regulatory gene p21 (Waf1/Cip1) and the BAX gene in sodium arsenite-exposed human keratinocyte HaCaT cells J. Biol. Chem. 286 30 2011 26860 26872
36. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli Adenoma prevention with celecoxib (APC) study investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N. Engl. J. Med. 352 2005 1071 1080
37. P. Srinath, P.N. Rao, E.E. Knaus, and M.R. Suresh Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation Anticancer Res. 23 2003 3923 3928
38. B. Takkouche, C. Regueira-Mendez, and M. Etminan Breast cancer and use of nonsteroidal anti-inflammatory drugs: a metaanalysis J. Nat. Cancer Inst. 100 2008 1439 1447
39. P. Teismann, K. Tieu, D.K. Choi, D.C. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, and S. Przedborski Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc. Natl. Acad. Sci. USA 100 9 2003 5473 5478
40. G. Valacchi, A. Pecorelli, M. Mencarelli, P. Carbotti, V. Fortino, M. Muscettola, and E. Maioli Rottlerin: a multifaced regulator of keratinocyte cell cycle Exp. Dermatol. 18 6 2009 516 521
41. G. Valacchi, P.A. Davis, E.M. Khan, R. Lanir, E. Maioli, A. Pecorelli, C.E. Cross, and T. Goldkorn Cigarette smoke exposure causes changes in Scavenger Receptor B1 level and distribution in lung cells Int. J. Biochem. Cell Biol. 43 7 2011 1065 1070
42. W.A. Van Gool, P.S. Aisen, and P. Eikelenboom Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J. Neurol. 250 2003 788 792
43. P. Wang, F. Zhu, N.H. Lee, and K. Konstantopoulos Shear-induced interleukin-6 synthesis in chondrocytes: roles of E prostanoid (EP) 2 and EP3 in cAMP/protein kinase A- and PI3-K/Akt-dependent NF-kappaB activation J. Biol. Chem. 285 32 2010 24793 24804